Regular Consumption of Both Vitamin D- and Calcium- and Vitamin D-Fortified Yogurt Drink Is Equally Accompanied by Lowered Blood Lipoprotein (a) and Elevated Apoprotein A1 in Subjects with Type 2 Diabetes: A Randomized Clinical Trial

Journal of the American College of Nutrition

Volumn 32, Issue 1, 2013, Pages 26-30

  Heravifard, Soudabeh ^a   Neyestani, Tirang R ^a   Nikooyeh, Bahareh ^a   Alavi Majd, Hamid ^a   Houshiarrad, Anahita ^a   Kalayi, Ali ^a   Shariatzadeh, Nastaran ^a   Zahedirad, Malihe ^a   Tayebinejad, Nima ^a   Salekzamani, Shabnam ^a   Khalaji, Niloufar ^a   Gharavi, A'azam ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

apoproteins; lipoprotein (a); type 2 diabetes; vitamin D

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CALCIFEDIOL; CALCIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN D; YOGHURT; LIPOPROTEIN; LIPOPROTEIN A; TRACE ELEMENT; CALCIUM INTAKE;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CLINICAL TRIAL; FEMALE; FOOD INTAKE; HUMAN; INSULIN SENSITIVITY; LIMIT OF DETECTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; BLOOD; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; RANDOMIZED CONTROLLED TRIAL; CARDIOVASCULAR DISEASES; COMPLICATION; PHARMACOLOGY; THERAPEUTIC USE;

ADULT; APOLIPOPROTEIN A-I; CALCIUM, DIETARY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FOOD, FORTIFIED; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS; MICRONUTRIENTS; MIDDLE AGED; VITAMIN D; YOGURT;

EID: 84893391214     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2013.767659     Document Type: Article

References (24)

1. Chiu, K C, Chu, A, Go, V LW and Saad, M F. 2004. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr, 79: 820 - 825.
2. Baz-Hecht, M and Goldfine, A B. 2010. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr Opin Endocrinol Diabetes Obes, 17: 113 - 119.
3. Worley, J R, Hughes, D A, Dozio, N, Gavrilovic, J and Sampson, M J. 2007. Low density lipoprotein from patients with type 2 diabetes increases expression of monocyte matrix metalloproteinase and ADAM metalloproteinase genes. Cardiovasc Diabetol, 6: 21 - 25.
4. Deans, K A and Dominiczak, M H. 2008. Hyperlipidaemia and cardiovascular disease: Apolipoprotein measurements and metabolic syndrome as predictors of cardiovascular risk. Curr Opin Lipidol, 19: 624 - 626.
5. Contois, J H, McConnell, J P, Sethi, A A, Csako, G, Devaraj, S, Hoefner, D M and Warnick, G R. 2009. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem, 55: 409 - 417.
6. Solfrizzi, V, Panza, F, Colacicco, A M, Capurso, C, D'Introno, A, Torres, F, Baldassarre, G and Capurso, A. 2002. Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or = 65 years of age (The Italian Longitudinal Study on Aging). Am J Cardiol, 89: 825 - 829.
7. Tarkun, I, Cetinarslan, B and Canturk, Z. 2002. Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: Relationship to metabolic parameters and diabetic complications. Nutr Metab Cardiovasc Dis, 12: 127 - 131.
8. Song, K H, Ko, S H, Kim, H W, Ahn, Y B, Lee, J M, Son, H S, Yoon, K H, Cha, B Y, Lee, K W and Son, H Y. 2005. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care, 28: 1718 - 1723.
9. Sarwar, N, Gao, P, Seshasai, S R, Gobin, R, Kaptoge, S, Di Angelantonio, E, Ingelsson, E, Lawlor, D A, Selvin, E, Stampfer, M, Stehouwer, C D, Lewington, S, Pennells, L, Thompson, A, Sattar, N, White, I R, Ray, K K and Danesh, J. 2010. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 375: 2215 - 2222.
10. Neyestani, T R, Gharavi, A and Kalayi, A. 2008. Iranian diabetics may not be vitamin D deficient more than healthy subjects. Acta Med Iran, 46: 337 - 341.
11. Jorde, R and Grimnes, G. 2012. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res, 50: 303 - 312.
12. Hosseinpanah, F, Yarjanli, M, Sheikholeslami, F, Heibatollahi, M, Eskandary, P S and Azizi, F. 2011. Associations between vitamin D and cardiovascular outcomes; Tehran Lipid and Glucose Study. Atherosclerosis, 218: 238 - 242.
13. Nikooyeh, B, Neyestani, T R, Farvid, M, Alavi-Majd, H, Houshiarrad, A, Kalayi, A, Shariatzadeh, N, Gharavi, A, Heravifard, S, Tayebinejad, N, Salekzamani, S and Zahedirad, M. 2011. Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: A randomized clinical trial. Am J Clin Nutr, 93: 764 - 771.
14. Neyestani, T R, Nikooyeh, B, Alavi-majd, H, Shariatzadeh, N, Kalayi, A, Tayebinejad, N, Heravifard, S, Salekzamani, S and Zahedirad, M. 2012. Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes. J Clin Endocrinol Metab, 97: 2005 - 2011.
15. Katz, A, Nambi, S S, Mather, K, Baron, A D, Follmann, D A, Sullivan, G and Quon, M J. 2000. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab, 85: 2402 - 2410.
16. Auwerx, J, Bouillon, R and Kesteloot, H. 1992. Relation between 25-hydroxyvitamin D3, apolipoprotein A-I, and high density lipoprotein cholesterol. Arterioscler Thromb, 12: 671 - 674.
17. John, W G, Noonan, K, Mannan, N and Boucher, B J. 2005. Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis. Am J Clin Nutr, 82: 517 - 522.
18. Kazlauskaite, R, Powell, L H, Mandapakala, C, Cursio, J F, Avery, E F and Calvin, J. 2010. Vitamin D is associated with atheroprotective high-density lipoprotein profile in postmenopausal women. J Clin Lipidol, 4: 113 - 119.
19. Ashton, W D, Nanchahal, K and Wood, D A. 2001. Body mass index and metabolic risk factors for coronary heart disease in women. Eur Heart J, 22: 46 - 55.
20. Dahlen, G H and Stenlund, H. 1997. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: Pathogenic mechanisms and clinical significance. Clin Genet, 52: 272 - 280.
21. Basson, M. 2011. Cardiovascular disease: Taking aim at Lp(a). Nat Med, 17: 1058
22. Maca, T, Mlekusch, W, Doweik, L, Budinsky, A C, Bischof, M, Minar, E and Schillinger, M. 2007. Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. Eur J Clin Invest, 37: 180 - 186.
23. Wehmeier, K, Beers, A, Haas, M J, Wong, N C, Steinmeyer, A, Zugel, U and Mooradian, A D. 2005. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta, 1737: 16 - 26.
24. Bisanz, J E and Reid, G. 2011. Unraveling how probiotic yogurt works. Sci Transl Med, 3: 106 - 141.